Boston Scientific Announces Equity Investment and Sales Cooperation Agreement with Preventice Solutions

2015-08-03

Houston and Rochester – Boston Scientific (NYSE: BSX) has become a significant shareholder and will become the exclusive worldwide sales and marketing representative for Preventice Solutions for cardiology-related diagnostic and monitoring offerings.

"This agreement marks an important strategic milestone for Preventice Solutions," said Jon Otterstatter, President and Chief Global Strategy Officer, co-CEO, Preventice Solutions. "We are thrilled to partner with Boston Scientific and collaborate on additional areas of mutual commercial and strategic interest. By partnering with Boston Scientific, we will expand our service capability and build a foundation for a future in the management of remote patient care," said John Untereker, Executive Vice President and Chief Operating Officer, co-CEO, Preventice Solutions.

The market for cardiac monitoring solutions is greater than $1B. Technologies include wearable monitors that detect and record heart rhythms such as Holter, cardiac event monitors (CEM), mobile cardiac telemetry (MCT) as well as implantable or insertable cardiac monitors. These products are often surrounded by monitoring services including data transmission, surveillance, reporting, interpretation, and integration into a provider's workflow. Preventice Solutions' portfolio includes PatientCare Platform and the BodyGuardian® range of products i.e. BodyGuardian® Heart, BodyGuardian® Verité and BodyGuardian® Holter.